| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
-hydroxysteroid dehydrogenase/type 5 17ß-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma
1 Department of Urology, University of Oklahoma Health Sciences Center, 920 Stanton L Young Blvd, WP3150, Oklahoma City, Oklahoma 73104, USA
2 Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
3 Department of Pharmacology, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania, USA
4 Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA
(Requests for offprints should be addressed to H-K Lin at Department of Urology, University of Oklahoma Health Sciences Center; Email: hk-lin{at}ouhsc.edu)
Type 2 3
-hydroxysteroid dehydrogenase (3-HSD) is a multi-functional enzyme that possesses 3-, 17ß- and 20-HSD, as well as prostaglandin (PG) F synthase activities and catalyzes androgen, estrogen, progestin and PG metabolism. Type 2 3-HSD was cloned from human prostate, is a member of the aldo-keto reductase (AKR) superfamily and was named AKR1C3. In androgen target tissues such as the prostate, AKR1C3 catalyzes the conversion of 
4-androstene-3,17-dione to testosterone, 5-dihydrotestosterone to 5-androstane-3,17ß-diol (3-diol), and 3-diol to androsterone. Thus AKR1C3 may regulate the balance of androgens and hence trans-activation of the androgen receptor in these tissues. Tissue distribution studies indicate that AKR1C3 transcripts are highly expressed in human prostate. To measure AKR1C3 protein expression and its distribution in the prostate, we raised a monoclonal antibody specifically recognizing AKR1C3. This antibody allowed us to distinguish AKR1C3 from other AKR1C family members in human tissues. Immunoblot analysis showed that this monoclonal antibody binds to one species of protein in primary cultures of prostate epithelial cells and in LNCaP prostate cancer cells. Immunohistochemistry with this antibody on human prostate detected strong nuclear immunoreactivity in normal stromal and smooth muscle cells, perineurial cells, urothelial (transitional) cells, and endothelial cells. Normal prostate epithelial cells were only faintly immunoreactive or negative. Positive immunoreactivity was demonstrated in primary prostatic adenocarcinoma in 9 of 11 cases. Variable increases in immunoreactivity for AKR1C3 was also demonstrated in non-neoplastic changes in the prostate including chronic inflammation, atrophy and urothelial (transitional) cell metaplasia. We conclude that elevated expression of AKR1C3 is highly associated with prostate carcinoma. Although the biological significance of elevated AKR1C3 in prostatic carcinoma is uncertain, AKR1C3 may be responsible for the trophic effects of androgens and/or PGs on prostatic epithelial cells.
This article has been cited by other articles:
|
|
 |
|
  N. J. Davies, R. E. Hayden, P. J. Simpson, J. Birtwistle, K. Mayer, J. P. Ride, and C. M. Bunce AKR1C Isoforms Represent a Novel Cellular Target for Jasmonates alongside Their Mitochondrial-Mediated Effects Cancer Res., June 1, 2009; 69(11): 4769 - 4775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M Day, H. J Tutill, A. Purohit, and M. J Reed Design and validation of specific inhibitors of 17{beta}-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis Endocr. Relat. Cancer, September 1, 2008; 15(3): 665 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Azzarello, K.-M. Fung, and H.-K. Lin Tissue Distribution of Human AKR1C3 and Rat Homolog in the Adult Genitourinary System J. Histochem. Cytochem., September 1, 2008; 56(9): 853 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Ji, L. Chang, F. Z. Stanczyk, M. Ookhtens, A. Sherrod, and A. Stolz Impaired Dihydrotestosterone Catabolism in Human Prostate Cancer: Critical Role of AKR1C2 as a Pre-Receptor Regulator of Androgen Receptor Signaling Cancer Res., February 1, 2007; 67(3): 1361 - 1369. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
